WORCESTER, Mass., Oct. 16, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that, at a conference earlier this week in Oran, Algeria, Generex, together with Continental Pharma Laboratories, the Company’s importation, marketing, distribution, and sales agent in Algeria, announced the launch of commercial sales of Generex Oral-lyn(TM) in Algeria. The product has been approved for importation and commercial marketing and sale in Algeria, and will be marketed and sold for the treatment of patients with Type-1 or Type-2 diabetes. The size of the diabetes population in the Eastern Mediterranean and Middle East region is approximately 24,500,000.
